Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer

Biomedicine and Pharmacotherapy

Volumn 67, Issue 8, 2013, Pages 763-769

  Xu, Bei ^a   Liu, Peng ^a   Yin, Yongmei ^a   Liu, Ping ^a   Shu, Yongqian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

First line; Non squamous non small cell lung cancer; Pemetrexed

Indexed keywords

CARBOPLATIN; CISPLATIN; OXALIPLATIN; PEMETREXED;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER MORTALITY; CANCER STAGING; CAUCASIAN; CHINESE; CONSTIPATION; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SMOKE; THROMBOCYTOPENIA;

FIRST-LINE; NON-SQUAMOUS NON-SMALL CELL LUNG CANCER; PEMETREXED;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 84887614541     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.04.013     Document Type: Article

References (28)

1. Feigenberg S.J., Hanlon A.L., Langer C., et al. A Phase II Study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stageII and IIIA non-small cell lung cancer. J Thorac Oncol 2007, 2(4):287-292.
2. Shepherd F.A. Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol 1993, 5(2):310-322.
3. Walling J. Chemotherapy for advanced non-small cell lung cancer. Respir Med 1994, 88(9):649-657.
4. Pfister D.G., Johnson D.H., Azzoli C.G., et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004, 22(2):330-353.
5. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98.
6. Breathnach O.S., Freidlin B., Conley B., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001, 19(6):1734-1742.
7. Ozasa H., Oguri T., Uemura T., et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 2010, 101(1):161-166. 10.1111/j.1349-7006.2009.01358.x.
8. Schultz R.M., Patel V.F., Worzalla J.F., et al. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate LY231514. Anticancer Res 1999, 19(1A):437-443.
9. Shih C., Habeck L.L., Mendelsohn L.G., et al. Multiple folate enzyme inhibition: Mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998, 38:135-152.
10. Vogelzang N.J., Rusthoven J.J., Symanowski, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644.
11. Cohen M.H., Johnson J.R., Wang Y.C., et al. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005, 10(6):363-368.
12. Gronberg B.H., Bremnes R.M., Flotten O., et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(19):3217-3224. 10.1200/JCO.2008.20.9114.
13. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551. 10.1200/JCO.2007.15.0375.
14. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22(9):1589-1597.
15. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(9699):1432-1440. 10.1016/S0140-6736(09)61497-5.
16. Scagliotti G., Hanna N., Fossella F., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14(3):253-263. 10.1634/theoncologist.2008-0232.
17. Zinner R.G., Novello S., Peng G., et al. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. Clin Lung Cancer 2010, 11(2):126-131. 10.3816/CLC.2010.n.017.
18. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
19. Ohe Y., Ichinose Y., Nakagawa K., et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008, 14(13):4206-4212. 10.1158/1078-0432.CCR-07-5143.
20. Holdenrieder S., von Pawel J., Dankelmann E., et al. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 2009, 63(1). 10.1016/j.lungcan.2008.05.001.
21. Manegold C., Gatzemeier U., von Pawel J., et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 2000, 11(4):435-440.
22. Kim Y.H., Hirabayashi M., Togashi Y., et al. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. Cancer Chemother Pharmacol 2012, 70(2):271-276. 10.1007/s00280-012-1910-2.
23. Yang C.H., Simms L., Park K., et al. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. J Thorac Oncol 2010, 5(5):688-695. 10.1097/JTO.0b013e3181d1273d.
24. Scagliotti G.V., Kortsik C., Dark G.G., et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial. Clin Cancer Res 2005, 11(2 Pt 1):690-696.
25. Zinner R.G., Fossella F.V., Gladish G.W., et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005, 104(11):2449-2456.
26. Jatoi A., Hillman S., Stella P., et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2005, 23(36):9113-9119.
27. Belani C.P., Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005, 104(12):2766-2774.
28. Vansteenkiste J., Ramlau R., von Pawel J., et al. A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemo-naive patients with advanced non-small cell lung cancer. Oncology 2012, 82(1):25-29. 10.1159/000335268.